HIV-1 Neutralization Profile and Plant-Based Recombinant Expression of Actinohivin, an Env Glycan-Specific Lectin Devoid of T-Cell Mitogenic Activity
Nobuyuki Matoba, Adam S. Husk, Brian W. Barnett et al. · 2010
Read HIV-1 Neutralization Profile and Plant-Based Recombinant Expression of Actinohivin, an Env Glycan-Specific Lectin Devoid of T-Cell Mitogenic Activity by Nobuyuki Matoba, Adam S. Husk, Brian W. Barnett et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0011143.txt.
Introduction
Matoba, Husk, Barnett and colleagues grew an HIV blocking protein in plants for PLOS ONE in 2010. The protein, from a sea organism, grabs the sugary coat of HIV and can stop the virus. The team made it in plant leaves and tested how well the plant made version blocked HIV.
The plant grown protein kept its blocking power and lacked a harmful side effect seen in similar proteins. Growing medicine in plants could lower cost and raise supply. That matters for prevention tools meant for wide use in poor regions. The study is an early step toward plant made HIV prevention.
Catalog record
| CREATOR | Nobuyuki Matoba, Adam S. Husk, Brian W. Barnett et al. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0011143
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
HIV-1 Neutralization Profile and Plant-Based Recombinant Expression of Actinohivin, an Env Glycan-Specific Lectin Devoid of T-Cell Mitogenic Activity Authors: Nobuyuki Matoba, Adam S. Husk, Brian W. Barnett, Michelle M. Pickel, Charles J. Arntzen, David C. Montefiori, Atsushi Takahashi, Kazunobu Tanno, Satoshi Omura, Huyen Cao, Jason P. Mooney, Carl V. Hanson, Haruo Tanaka Published: 2010, PLOS ONE DOI: 10.1371/journal.pone.0011143 ABSTRACT The development of a topical microbicide blocking the sexual transmission of HIV-1 is urgently needed to control the global HIV/AIDS pandemic. The actinomycete-derived lectin actinohivin (AH) is highly specific to a cluster of high-mannose-type glycans uniquely found on the viral envelope (Env). Here, we evaluated AH's candidacy toward a microbicide in terms of in vitro anti-HIV-1 activity, potential side effects, and recombinant producibility. Two validated assay systems based on human peripheral blood mononuclear cell (hPBMC) infection with primary isolates and TZM-bl cell infection with Env-pseudotyped viruses were employed to characterize AH's anti-HIV-1 activity. In hPMBCs, AH exhibited nanomolar neutralizing activity against primary viruses with diverse cellular tropisms, but did not cause mitogenicity or cytotoxicity that are often associated with other anti-HIV lectins. In the TZM-bl-based assay, AH showed broad anti-HIV-1 activity against clinically-relevant, mucosally transmitting strains of clades B and C. By contrast, clade A viruses showed strong resistance to AH. Correlation analysis suggested that HIV-1′s AH susceptibility is significantly linked to the N -glycans at the Env C2 and V4 regions. For recombinant (r)AH expression, we evaluated a tobacco mosaic virus-based system in Nicotiana benthamiana plants as a means to facilitate molecular engineering and cost-effective mass production. Biochemical analysis and an Env-mediated syncytium formation assay demonstrated high-level expression of functional rAH within six days. Taken together, our study revealed AH's cross-clade anti-HIV-1 activity, apparent lack of side effects common to lectins, and robust producibility using plant biotechnology. These findings justify further efforts to develop rAH toward a candidate HIV-1 microbicide. INTRODUCTION For nearly 30 years, HIV has posed serious global health concerns. Millions of new HIV infections are reported every year worldwide, mainly in developing regions where the availability of antiretroviral drug therapies is extremely limited. As a result, AIDS is among the leading causes of death in these regions [1] . The majority of infections are established via heterosexual transmission and condom use is currently the only available means to directly block this route of infection. As such, the need is urgent for woman-controlled, safe, effective, and inexpensive topical microbicides, until prophylaxis through vaccination becomes globally available [2] , [3] . Current candidate microbicides under development encompass chemical and physical agents as well as biologicals, including virion-inactivating agents, entry/fusion inhibitors, reverse transcriptase inhibitors, and others ( www.microbicide.org ). At this point, it is not known which type of anti-HIV agents will be most effective as topical microbicides; blocking of HIV-1 mucosal transmission may require combinations of multiple agents [4] , [5] . Therefore, to broaden the options for different combinations in HIV-1 microbicide development, it is important to expand the candidate portfolio in each category of possible microbicide components. The envelope (Env) gp120 is heavily glycosylated with N- linked glycans (NLGs), which generally account for more than half of the protein's molecular mass [6] . Of these, HMGs represent a major class. Because the Env glycans play critical roles in broad aspects of the viral life cycle ranging from Env folding in host cells to viral transmission and immune escape [7] , they constitute an attractive target for entry/fusion inhibitor-based microbicide development. Lectins have attracted considerable attention in the search for Env glycan-targeting microbicide candidates. Indeed, various naturally occurring lectins have been shown to possess anti-HIV activities. Examples include algae-derived cyanovirin-N (CV-N) and griffithsin (GRFT) as well as plant-derived concanavalin A (Con A) and snowdrop lectin, among others (reviewed in: [7] ). More recently, a Jacalin-related lectin isolated from the banana fruit was shown to potently inhibit HIV-1 entry into target cells [8] . Although conceptually not a lectin, the human monoclonal antibody (mAb) 2G12 specifically binds to gp120 HMGs and thereby neutralizes a wide spectrum of HIV-1 strains; thus, it is counted among the very few broadly neutralizing mAbs isolated to date [9] , [10] . AH was isolated from the actinomycete strain Longispora albida K97-0003 T based on the inhibitory activity in a syncytium formation assay [11] . A recent crystallographic analysis revealed that AH is a monomeric protein and possesses three carbohydrate-binding sites [12] . Unlike several other known monosaccharide-specific anti-HIV lectins such as GRFT, Con A, and Galanthus nivalis agglutinin [7] , AH specifically recognizes a cluster of multiple HMGs via a collaborative action among the protein's three sugar-binding sites [12] , [13] . Because clustering HMGs is a unique feature of Env glycans and not usually found on host human proteins [14] , AH is hypothesized to be a superior anti-HIV-1 lectin with exquisite specificity to the virus; hence, it may be devoid of unfavorable biological impacts in humans. In spite of the detailed studies in AH's carbohydrate-binding specificity [12] , [13] , [15] , limited investigation has been reported with regard to the protein's anti-HIV activity in a syncytium formation assay and in a multinuclear-activation-of-galactosidase-indicator (MAGI) assay [15] . Because there is currently no in vitro assay that can accurately predict in vivo efficacy of a candidate anti-HIV-1 agent, it is important to evaluate the activity of a potential anti-HIV compound in multiple in vitro assay systems, preferably, those that can closely simulate the in vivo situation and analyze anti-HIV-1 activity in a broad-spectrum of clinically relevant viruses from different clades [16] . Another important factor for a protein-based microbicide candidate is the development of an efficient, cost-effective recombinant expression system that is compatible with extensive preclinical and clinical studies, global distribution, and molecular design for the construction of stronger and/or safer derivatives. Thus, the primary objectives of our study were to reveal AH's anti-HIV-1 potential in validated in vitro neutralization assay systems and to develop a robust expression platform for rAH. To this end, we employed a human peripheral blood mononuclear cell (hPBMC)-based neutralization assay using primary HIV-1 isolates and a reporter gene expressing TZM-bl cell-based neutralization assay using Env-pseudotyped viruses from diverse clades, including clinically relevant C-C chemokine receptor 5-tropic (R5) HIV-1 strains. For recombinant expression of AH, we tested a rapid and robust tobacco mosaic virus (TMV)-based expression system in Nicotiana benthamiana plants. Thus, we provide data implicating the feasibilities of AH in terms of its efficacy and production viability. In addition, we performed a preliminary analysis of AH to screen for potential side effects commonly noted with antiviral lectins, i.e., cytotoxicity and mitogenic activity in hPBMCs. METHODS The hPBMCs used in the HIV neutralization assay and proliferation analysis described below were purchased from the local blood center (American Red Cross Blood Center, Oakland, CA) as an otherwise-discarded by-product of unsolicited blood donations. No information about identity of the donors was available to the investigators. The assay was conducted essentially as described in D'Souza et al. [17] and Mascola et al. [18] . Accordingly, the infectious viruses were produced in hPBMCs. The hPBMCs were prepared from buffy coats using Lymphocyte Separation Medium (LSM; Cappel, Aurora, OH). To reduce variation of data from different cell preparations, the cell samples from four